Related Experiment Video
Updated: Jun 15, 2026
13:47
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
[Recent and future development of anti-HIV agents]
Masayuki Amano1, Hiroaki Mitsuya
1Department of Hematology, Kumamoto University Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 17, 2010
Summary
Antiretroviral therapies have significantly improved acquired immune deficiency syndrome (AIDS) treatment. New challenges in AIDS therapy require continued research for more effective HIV control strategies.
Area of Science:
- Virology
- Immunology
- Pharmacology
Context:
- Over 25 years of research have yielded numerous antiretroviral agents for acquired immune deficiency syndrome (AIDS).
- Combination chemotherapy has substantially reduced AIDS-related morbidity and mortality.
- Current challenges in AIDS therapy differ from initial drug development hurdles.
Purpose:
- To highlight the evolution of AIDS therapy.
- To underscore the ongoing challenges in managing HIV infection.
- To advocate for continued research into novel treatment modalities.
Summary:
- Antiretroviral drugs and combination chemotherapy have transformed AIDS treatment, improving patient outcomes.
- Despite progress, significant challenges remain in managing HIV infection effectively.
- The forefront of HIV therapy necessitates the exploration of new, more potent antiviral agents.
Impact:
- Advances in antiretroviral therapy have drastically improved the prognosis for individuals with HIV/AIDS.
- Addressing new therapeutic challenges is crucial for enhancing the control of HIV diseases.
- Continued innovation in antiviral drug development offers hope for more efficient and effective HIV management.
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...